Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour

Clin Endocrinol (Oxf). 2014 Dec;81(6):940-2. doi: 10.1111/cen.12519. Epub 2014 Jul 2.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Denosumab
  • Humans
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / etiology
  • Hypocalcemia / chemically induced*
  • Male
  • Neuroendocrine Tumors / complications
  • Neuroendocrine Tumors / metabolism
  • Pancreatic Neoplasms / complications
  • Pancreatic Neoplasms / metabolism
  • Paraneoplastic Syndromes / drug therapy*
  • Paraneoplastic Syndromes / etiology
  • Parathyroid Hormone-Related Protein / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Parathyroid Hormone-Related Protein
  • Denosumab

Supplementary concepts

  • Humoral Hypercalcemia Of Malignancy